MX2020011234A - Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). - Google Patents
Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).Info
- Publication number
- MX2020011234A MX2020011234A MX2020011234A MX2020011234A MX2020011234A MX 2020011234 A MX2020011234 A MX 2020011234A MX 2020011234 A MX2020011234 A MX 2020011234A MX 2020011234 A MX2020011234 A MX 2020011234A MX 2020011234 A MX2020011234 A MX 2020011234A
- Authority
- MX
- Mexico
- Prior art keywords
- nlrp3
- modulators
- nlrp3 modulators
- compounds
- medicaments
- Prior art date
Links
- 101150061038 NLRP3 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662240P | 2018-04-25 | 2018-04-25 | |
| US201862764818P | 2018-08-16 | 2018-08-16 | |
| US201962825044P | 2019-03-28 | 2019-03-28 | |
| PCT/US2019/028823 WO2019209896A1 (en) | 2018-04-25 | 2019-04-24 | Nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011234A true MX2020011234A (es) | 2020-11-11 |
Family
ID=66677224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011234A MX2020011234A (es) | 2018-04-25 | 2019-04-24 | Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12037344B2 (enExample) |
| EP (2) | EP4353235A3 (enExample) |
| JP (2) | JP7351850B2 (enExample) |
| KR (1) | KR102711180B1 (enExample) |
| CN (2) | CN112074516A (enExample) |
| AU (1) | AU2019261582A1 (enExample) |
| BR (1) | BR112020021539A2 (enExample) |
| CA (1) | CA3097865A1 (enExample) |
| CL (1) | CL2020002719A1 (enExample) |
| CO (2) | CO2020013155A2 (enExample) |
| ES (1) | ES2971122T3 (enExample) |
| IL (1) | IL278173A (enExample) |
| MX (1) | MX2020011234A (enExample) |
| NZ (1) | NZ769136A (enExample) |
| PE (1) | PE20210160A1 (enExample) |
| SG (1) | SG11202010463TA (enExample) |
| TW (1) | TW202014420A (enExample) |
| WO (1) | WO2019209896A1 (enExample) |
| ZA (1) | ZA202007307B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4087842A1 (en) * | 2020-01-10 | 2022-11-16 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| AU2021254794A1 (en) * | 2020-04-16 | 2022-12-15 | Incyte Corporation | Fused tricyclic KRAS inhibitors |
| MX2022013637A (es) | 2020-04-30 | 2022-11-16 | Janssen Pharmaceutica Nv | Nuevos compuestos de triazinoindol. |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| AU2021279305A1 (en) * | 2020-05-28 | 2023-02-09 | Janssen Pharmaceutica Nv | Compounds |
| CN116390923B (zh) * | 2020-08-21 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| EP3984535A1 (en) * | 2020-10-16 | 2022-04-20 | Albert-Ludwigs-Universität Freiburg | Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome |
| WO2022115377A1 (en) * | 2020-11-24 | 2022-06-02 | Amgen Inc. | Tricyclic carboxamide derivatives as prmt5 inhibitors |
| CN114539095A (zh) * | 2020-11-26 | 2022-05-27 | 乐凯化学材料有限公司 | 3-（4-羟基-3-甲氧基-苯基）-2-氰基-2-丙烯酸乙酯的制备方法 |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| MX2024000357A (es) | 2021-07-07 | 2024-02-12 | Incyte Corp | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). |
| WO2023287896A1 (en) | 2021-07-14 | 2023-01-19 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| CN117940120A (zh) * | 2021-07-16 | 2024-04-26 | 戴纳立制药公司 | 化合物、组合物和方法 |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| WO2025190317A1 (en) * | 2024-03-13 | 2025-09-18 | National Institute Of Biological Sciences, Beijing | Urea compounds as nlrp3 agonists |
| WO2026006603A1 (en) * | 2024-06-26 | 2026-01-02 | Wisconsin Alumni Research Foundation | Tlr7/tlr8 agonists for use in trifunctional radiopharmaceutical compounds |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| US20090075980A1 (en) | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| KR20060120069A (ko) | 2003-10-03 | 2006-11-24 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
| US20070259907A1 (en) | 2004-06-18 | 2007-11-08 | Prince Ryan B | Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
| US20080193468A1 (en) * | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
| US8378102B2 (en) | 2005-02-09 | 2013-02-19 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| JP2010535844A (ja) | 2007-08-14 | 2010-11-25 | ノバルティス アーゲー | Ｇａｂａアルファリガンドとしてのピラゾロキノリンおよびピラゾロナフチリジン誘導体 |
| US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| AU2012244549B2 (en) | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| SI2573073T1 (sl) | 2011-09-26 | 2015-02-27 | Sanofi | Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104418867B (zh) * | 2013-08-26 | 2016-12-28 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015095780A1 (en) | 2013-12-20 | 2015-06-25 | The University Of Kansas | Toll-like receptor 8 agonists |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN121243402A (zh) | 2014-07-09 | 2026-01-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1组合 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| WO2016199943A1 (en) | 2015-06-11 | 2016-12-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR20180040706A (ko) | 2015-09-01 | 2018-04-20 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도 |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| CN105523955B (zh) * | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN108029076B (zh) | 2016-02-02 | 2020-03-10 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| KR20180134395A (ko) | 2016-04-19 | 2018-12-18 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| US11344543B2 (en) | 2017-07-14 | 2022-05-31 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| KR102709679B1 (ko) | 2018-04-25 | 2024-09-26 | 바이엘 악티엔게젤샤프트 | 살충제로서의 신규 헤테로아릴-트리아졸 및 헤테로아릴-테트라졸 화합물 |
-
2019
- 2019-04-24 PE PE2020001652A patent/PE20210160A1/es unknown
- 2019-04-24 EP EP23211253.2A patent/EP4353235A3/en active Pending
- 2019-04-24 WO PCT/US2019/028823 patent/WO2019209896A1/en not_active Ceased
- 2019-04-24 US US17/049,612 patent/US12037344B2/en active Active
- 2019-04-24 SG SG11202010463TA patent/SG11202010463TA/en unknown
- 2019-04-24 CA CA3097865A patent/CA3097865A1/en active Pending
- 2019-04-24 NZ NZ769136A patent/NZ769136A/en unknown
- 2019-04-24 KR KR1020207033384A patent/KR102711180B1/ko active Active
- 2019-04-24 JP JP2020559472A patent/JP7351850B2/ja active Active
- 2019-04-24 ES ES19727780T patent/ES2971122T3/es active Active
- 2019-04-24 CN CN201980027881.7A patent/CN112074516A/zh active Pending
- 2019-04-24 CN CN202011468364.4A patent/CN112521387B/zh active Active
- 2019-04-24 AU AU2019261582A patent/AU2019261582A1/en not_active Abandoned
- 2019-04-24 BR BR112020021539-2A patent/BR112020021539A2/pt not_active IP Right Cessation
- 2019-04-24 EP EP19727780.9A patent/EP3784670B1/en active Active
- 2019-04-24 MX MX2020011234A patent/MX2020011234A/es unknown
- 2019-04-25 TW TW108114491A patent/TW202014420A/zh unknown
-
2020
- 2020-10-20 IL IL278173A patent/IL278173A/en unknown
- 2020-10-21 CO CONC2020/0013155A patent/CO2020013155A2/es unknown
- 2020-10-21 CL CL2020002719A patent/CL2020002719A1/es unknown
- 2020-10-21 CO CONC2021/0006672A patent/CO2021006672A2/es unknown
- 2020-11-24 ZA ZA2020/07307A patent/ZA202007307B/en unknown
-
2023
- 2023-09-14 JP JP2023149057A patent/JP7660634B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210267964A1 (en) | 2021-09-02 |
| PE20210160A1 (es) | 2021-01-26 |
| NZ769136A (en) | 2024-04-26 |
| KR20210005106A (ko) | 2021-01-13 |
| CN112074516A (zh) | 2020-12-11 |
| KR102711180B1 (ko) | 2024-09-26 |
| CO2020013155A2 (es) | 2021-06-10 |
| CN112521387B (zh) | 2023-08-22 |
| TW202014420A (zh) | 2020-04-16 |
| CA3097865A1 (en) | 2019-10-31 |
| BR112020021539A2 (pt) | 2021-01-19 |
| EP3784670A1 (en) | 2021-03-03 |
| EP3784670B1 (en) | 2023-11-29 |
| JP2024001030A (ja) | 2024-01-09 |
| SG11202010463TA (en) | 2020-11-27 |
| CO2021006672A2 (es) | 2021-06-10 |
| IL278173A (en) | 2020-11-30 |
| JP7351850B2 (ja) | 2023-09-27 |
| ZA202007307B (en) | 2023-01-25 |
| ES2971122T3 (es) | 2024-06-03 |
| EP4353235A3 (en) | 2024-07-31 |
| CL2020002719A1 (es) | 2020-12-18 |
| JP2021522249A (ja) | 2021-08-30 |
| US12037344B2 (en) | 2024-07-16 |
| EP4353235A2 (en) | 2024-04-17 |
| WO2019209896A1 (en) | 2019-10-31 |
| AU2019261582A1 (en) | 2020-11-12 |
| CN112521387A (zh) | 2021-03-19 |
| JP7660634B2 (ja) | 2025-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011234A (es) | Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). | |
| NZ761519A (en) | Nlrp3 modulators | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| GEAP201914678A (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| NZ750174A (en) | Somatostatin modulators and uses thereof | |
| GEP20207160B (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| MX2019014876A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| CR20190537A (es) | Inhibidores pirazólicos de magl | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
| SA521422152B1 (ar) | Vanin مركبات عطرية غير متجانسة كمثبطات | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| NZ797704A (en) | Dual magl and faah inhibitors | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| JOP20200090A1 (ar) | عملية لتحضير بنزوثيوفين-2 يل بورونات | |
| WO2016187620A3 (en) | Anti-cancer compounds | |
| EA202092539A1 (ru) | Модуляторы nlrp3 | |
| EA202090283A1 (ru) | Модуляторы nlrp3 |